ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0168

Renal Tubular-Specific NRF2 Activity Protects Against Aristolochic Acid Nephropathy

Session Information

  • AKI: Mechanisms - 3
    November 08, 2025 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 103 AKI: Mechanisms

Authors

  • Stewart, Joy A., University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania, United States
  • Gilbert, Josie, University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania, United States
  • Hartman, Hannah L., University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania, United States
  • Bondi, Corry D., University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania, United States
  • Subramanya, Arohan R., University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania, United States
  • Tan, Roderick J., University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania, United States
Background

Aristolochic Acid Nephropathy (AAN) is a kidney disease caused by nephrotoxin exposure leading to tubulointerstitial injury, inflammation, fibrosis, and end stage renal disease. AAN can be induced in mice as a model of kidney disease. The KEAP1/NRF2 pathway is a cytoprotective pathway responsible for upregulating antioxidant and detoxifying genes at times of cellular stress. KEAP1 is an inhibitor of NRF2 and prevents this transcription factor from upregulating target genes including NAD(P)H quinone oxidoreductase 1 (Nqo1). Previous studies have shown that NRF2 activity protects against tubular injuries, but the role of NRF2 in AAN is unknown. We enhanced tubular-specific NRF2 activity by generating conditional Keap1 knockouts and exposed these mice and wild-type littermates to AAN injury. We hypothesized that tubular NRF2 activity is protective against AAN in mice.

Methods

To generate tubular-specific Keap1 knockout mice we crossed Keap1 floxed animals with tubular-specific Cre expressing mice using the Pax8-Lc1 system. Doxycycline was administered for two weeks (2g/L in drinking water) to induce knockout prior to injection of aristolochic acid type I (5mg/kg i.p. thrice weekly x 1-2 weeks) to induce AAN. Glomerular filtration rates (GFR) were measured using transcutaneous probes and FITC-sinistrin. Serum and kidney tissue were collected to measure blood urea nitrogen (BUN) and injury biomarkers.

Results

Keap1 knockout mice exhibited increased Nqo1 protein levels in renal tubules at baseline, indicating higher NRF2 activity. As expected, AAN decreased GFR and increased BUN. Keap1 knockout mice were protected from these changes and exhibited improvements in biomarkers of kidney injury including α-SMA, fibronectin, TNF-α, MCP-1, and IL-1β.

Conclusion

Tubular-specific conditional Keap1 knockout increases NRF2 activity. These mice are protected from AAN, suggesting that tubular NRF2 is protective against this injury. Targeting NRF2 may be an effective treatment for this disease.

Funding

  • NIDDK Support

Digital Object Identifier (DOI)